Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Shares of Viking Therapeutics VKTX rose nearly 8% on Friday after several third-party reports suggested that it was being ...

Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 ...

Many investors may have been hoping that another, larger healthcare company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening. And with a ...

Despite higher expenses, including a net loss of $35.4 million in Q4 and a full-year loss of $110.0 million, the corporation is investing heavily in its clinical programs, particularly for VK2735 ...

In the second quarter of 2025, the business intends to start Phase 3 studies for their subcutaneous obesity therapy, VK2735. Targeting metabolic and endocrine diseases, the San Diego-based ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25. VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose ...